ISMRM/QIBA PDFF Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 12: | Line 12: | ||
<br />Notes are posted after they are approved by the PDFF BC during the following t-con. The last meeting was on February 3, 2022. | <br />Notes are posted after they are approved by the PDFF BC during the following t-con. The last meeting was on February 3, 2022. | ||
*[[Media:2022_02-03_QIBA_PDFF_BC_Meeting_Summary-FINAL.pdf|February 3, 2022]] | |||
*[[Media:2021_04-01_QIBA_PDFF_BC_Meeting_Summary-FINAL.pdf|April 1, 2021]] | *[[Media:2021_04-01_QIBA_PDFF_BC_Meeting_Summary-FINAL.pdf|April 1, 2021]] | ||
*[[Media:2021_02-04_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|February 4, 2021]] | *[[Media:2021_02-04_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|February 4, 2021]] | ||
'''''[[PDFF Biomarker Committee Call Summaries Archive]]''''' | '''''[[PDFF Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 15:48, 26 January 2023
- Co-chairs: Scott Reeder, MD, PhD; Takeshi Yokoo, MD, PhD
- ISMRM Staff Support: Roberta A. Kravitz; Anne Marie Kahrovic
The PDFF Biomarker Committee seeks to develop a quantitative Profile for PDFF. This effort is supported by ISMRM, using the QIBA Process for Profile development.
Meetings
Approved call summaries:
Notes are posted after they are approved by the PDFF BC during the following t-con. The last meeting was on February 3, 2022.
PDFF Biomarker Committee Call Summaries Archive